390815-41-5

Basic information

• Product Name: (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride
• Synonyms: (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride;(R)-1-(3,4-DIMETHOXYPHENYL)ETHANAMINE HCL
• CAS NO: 390815-41-5
• Molecular Formula: C10H16ClNO2
• Molecular Weight: 217.69254
• Mol File: 390815-41-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride(390815-41-5)
• EPA Substance Registry System: (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride(390815-41-5)

Safety Data

• Hazardous Substances Data: 390815-41-5(Hazardous Substances Data)

Usage

Description

(R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride, a chemical compound with the molecular formula C10H15NO2Cl, is a potent psychoactive substance known for its central nervous system stimulant properties. It is a derivative of amphetamine and primarily functions by modulating the levels of dopamine and norepinephrine in the brain. (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is typically administered as a hydrochloride salt, which enhances its stability and solubility in water, making it suitable for medical applications.

Uses

Used in Pharmaceutical Industry:
(R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is utilized as a therapeutic agent for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its mechanism of action involves the modulation of neurotransmitter levels, specifically dopamine and norepinephrine, which helps in managing the symptoms of these conditions.
Used in Central Nervous System Stimulation:
As a central nervous system stimulant, (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is employed to enhance cognitive function and alertness. Its psychoactive properties make it a valuable compound in the development of medications aimed at improving focus, attention, and reducing impulsivity in individuals with ADHD.
Used in Treatment of Narcolepsy:
(R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride is also used in the management of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of muscle weakness. (R)-1-(3,4-Dimethoxyphenyl)ethanamine hydrochloride's ability to stimulate the central nervous system helps in reducing the frequency and severity of these symptoms, thereby improving the quality of life for those affected by narcolepsy.

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 937028-41-6 (R_S,R)-(-)-N-[1-(3,4-dimethoxyphenyl)ethyl]-2-methylpropanesulfinamide 
• 820231-38-7 (R)-(-)-N-(3,4-dimethoxybenzylidene)-2-methylpropanesulfinamide 
• 906528-66-3 (R_S,S)-(-)-N-[1-(3,4-dimethoxyphenyl)ethyl]-2-methylpropanesulfinamide 

Relevant articles and documents

Total synthesis of (R)-(+)-salsolidine by hydride addition to (R)-N-tert-butanesulfinyl ketimine

(R)-(+)-Salsolidine 1 of high enantiomeric purity was synthesized using the Pomeranz-Fritsch-Bobbitt methodology, in which the reduction (NaBH4, DIBAL-H) of N-tert-butanesulfinyl ketimine, derived from 3,4-dimethoxyacetophenone, was the key ste

Chiral Bronsted Acids Catalyze Asymmetric Additions to Substrates that Are Already Protonated: Highly Enantioselective Disulfonimide-Catalyzed Hantzsch Ester Reductions of NH-Imine Hydrochloride Salts

While imines are frequently used substrates in asymmetric Bronsted acid catalysis, their corresponding salts are generally considered unsuitable reaction partners. Such processes are challenging because they require the successful competition of a catalytic amount of a chiral anion with a stoichiometric amount of an achiral one. We now show that enantiopure disulfonimides enable the asymmetric reduction of N-H imine hydrochloride salts using Hantzsch esters as hydrogen source. Our scalable reaction delivers crystalline primary amine salts in great efficiency and enantioselectivity and the discovery suggests potential of this approach in other Bronsted acid catalyzed transformations of achiral iminium salts. Kinetic studies and acidity data suggest a bifunctional catalytic activation mode.

Viral polymerase inhibitors

A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-3)alkyl, (C6-10)bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R3 is selected from H, (C1-6)alkyl, (C3-6)cycloalkyl, (C36)cycloalkyl(C1-6)alkyl, (C6-10)aryl, (C6-10)aryl(C1-6)alkyl, (C2-6)alkenyl, (C3-6)cycloalkyl(C2-6)alkenyl, (C6-10)aryl(C2-6)alkenyl, N{(C1-6)alkyl}2, NHCOO(C1-6)alkyl(C6-10)aryl, NHCO(C6-10)aryl, (C1-6)alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.